Katherine Vega Stultz is the CEO and president of Ocelot Bio, a clinical-stage biotech company focused on the development of therapeutics to treat complications of end-stage liver disease.
Enrollment ongoing in expansion portion of Phase 1/2 KB-0742 study, with initial efficacy data expected in 2H 2023 Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML. | May 10, 2023
Katherine Vega Stultz appointed to Board Current Board member Otello Stampacchia, Ph.D., stepped down SAN MATEO, Calif. and CAMBRIDGE, Mass., April 11, 2023 Kronos Bio, Inc. , a company. | June 20, 2023